DUBLIN--(BUSINESS WIRE)--The "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the BPDCN, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Disease Understanding
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), is a rare, highly aggressive, difficult-to-diagnose hematologic malignancy with a poor prognosis. It is derived from the precursors of plasmacytoid dendritic cells (pDCs) - immune cells that specialize in the production of type I interferons in response to bacterial and viral stimuli. Patients with BPDCN have diverse clinical features, with cutaneous tumors in nearly all cases; the high incidence of such tumors distinguishes this disease from other myeloid cancers. Other sites of involvement include bone marrow, peripheral blood, lymph nodes, spleen, and other extramedullary organs. BPDCN can also evolve from prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), so patients with such diseases and skin lesions should be evaluated for BPDCN specifically.
Following the microscopical tissue examination, immunophenotyping is routinely used to confirm the diagnosis of BPDCN, by demonstrating that the cancer cells are positive for CD4, CD56, and CD123. This is known as the classic triad for the diagnosis of BPDCN. Up to 90% of patients with BPDCN show an initial response to combination chemotherapy, but relapses with subsequent resistance to drugs are regularly observed.
Scope of the Report
- The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Epidemiology Report and Model provide an overview of the risk factors and global trends of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of BPDCN
- The report provides the segmentation of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology by Incident Cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM.
- The report provides the segmentation of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology by gender-specific Incident Cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM.
- The report provides the segmentation of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology by age-specific Prevalent Cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM.
Report Highlights
- 11-Year Forecast of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology
- 7MM Coverage
- Total Incident Cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Incident Cases according to segmentation: Gender-specific cases of BPDCN
- Prevalent Cases according to segmentation: Age-specific cases of BPDCN
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to BPDCN?
- What are the key findings pertaining to the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What is the disease risk, burden and unmet needs of the BPDCN?
- What are the currently available treatments of BPDCN?
Key Topics Covered:
1. Key Insights
2. Executive summary
3. Organizations
4. Epidemiology and Market Methodology
5. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Patient Overview at a Glance
5.1. Total Patient Share (%) Distribution of BPDCN in 2017
5.2. Total Patient Share (%) Distribution of BPDCN in 2030
6. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Disease Overview
6.1. Introduction
6.2. Classification
6.3. Clinical Presentation
6.4. Pathogenesis
6.5. Diagnosis
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM
7.3. United States
7.3.1. Assumptions and Rationale
7.3.2. Total Incident cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.3.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.3.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.4. EU5 Countries
7.5. Assumptions and Rationale
7.6. Germany
7.7. France
7.8. Italy
7.9. Spain
7.10. UK
7.11. Japan
8. Current Treatment Practices
8.1. Treatment Algorithm
9. Appendix
10. Report Methodology
11. Capabilities
12. Disclaimer
13. About the Publisher
14. Bibliography
For more information about this report visit https://www.researchandmarkets.com/r/pv86oq
